Fda argatroban label direct thrombin inhibitor?

Question

Accepted Answer

FDA Label Summary – Argatroban (ARGINEM®)
(Direct Thrombin Inhibitor – IV formulation)

Section	Key Points
Indication	• Prevention and treatment of acute thromboembolic events (including pulmonary embolism and deep‑vein thrombosis) in patients with heparin‑induced thrombocytopenia (HIT) or with an absolute contraindication to heparin. • Used in patients undergoing cardiac surgery when heparin cannot be used.
Dosage & Administration	• Initial infusion: 2 µg kg⁻¹ min⁻¹ (IV bolus may be given in special cases). • Goal: Maintain aPTT (activated partial thromboplastin time) 1.5–3.0 × baseline (or 60–100 sec, whichever is higher). • Dose adjustment: Increase or decrease by 0.5‑1 µg kg⁻¹ min⁻¹ every 15 min until target aPTT is achieved; thereafter titrate to keep aPTT within range. • Maximum dose: 10 µg kg⁻¹ min⁻¹ (unless clinically indicated). • Monitoring: aPTT every 15–30 min until stable; then every 4–6 h during therapy and again 1 h after discontinuation.
Contraindications	• Active major bleeding or significant risk of bleeding. • Severe hepatic dysfunction (Child‑Pugh Class C) or impaired drug clearance.
Warnings & Precautions	• Bleeding: Major bleeding risk, especially in patients with recent surgery or intracranial hemorrhage. • Platelet function: Not suitable for patients with platelet count <50 × 10⁶ L⁻¹. • Drug interactions: Concomitant use with warfarin, DOACs, or other anticoagulants may increase bleeding; dose of concomitant anticoagulant should be reduced and carefully monitored. • Renal function: Argatroban is cleared hepatically; no dose adjustment in renal impairment, but monitor for accumulation in severe hepatic disease.
Adverse Reactions (≥10 % in clinical trials)	• Hemorrhage (major and minor), epistaxis, bleeding gums, bruising, and anemia. • Thrombocytopenia (rare).
Pharmacokinetics	• Onset: Rapid, 1–2 min IV. • Half‑life: ~15–30 min (dose‑dependent). • Metabolism: Hepatic (non‑renal). • Excretion: Biliary.
Drug Interaction Summary	• Warfarin: Additive anticoagulant effect; INR may rise. • DOACs (apixaban, rivaroxaban, dabigatran, edoxaban): Potential additive bleeding; consider dose reduction. • Other anticoagulants (e.g., unfractionated heparin, LMWH, direct factor Xa inhibitors): Avoid overlapping unless clinically justified; monitor aPTT or anti‑Xa. • CYP inhibitors/inducers: Minimal effect; no dose adjustment needed.
Use in Special Populations	• Pregnancy: Category C; use only if potential benefit outweighs risk. • Pediatrics: No approved indications; use with extreme caution.
Storage	• Reconstituted solution: 4–8 °C; protected from light. • Shelf life: 30 days after reconstitution.
Key Lab Monitoring	• aPTT (primary). • Platelet count (daily). • Liver function tests if prolonged therapy.

Practical Tips for Clinicians

Start with the 2 µg kg⁻¹ min⁻¹ infusion and titrate based on aPTT, not on fixed dose steps.
If a patient has liver impairment (Child‑Pugh B or C), be prepared for prolonged drug action; monitor aPTT more frequently and consider lower starting rates.
When switching from warfarin or a DOAC to argatroban for urgent surgery, allow at least 12 h after last DOAC dose before initiating argatroban.
During discontinuation, stop infusion and re‑check aPTT 1 h later; most patients will be within therapeutic range within 30–60 min.
Document all dose adjustments, aPTT results, and clinical signs of bleeding in the chart.

Reference – FDA prescribing information for Arginem™ (argatroban) as of the most recent update (2024).

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Fda argatroban label direct thrombin inhibitor?

Practical Tips for Clinicians